Lixte Biotechnology Holdings Inc
LIXT
Company Profile
Business description
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.
Contact
433 Plaza Real
Suite 275
Boca RatonFL33432
USAT: +1 631 830-7092
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
3
Stocks News & Analysis
stocks
Ask the analyst: Where does GYG stand following its US exit?
All roads lead back home for Guzman Y Gomez.
stocks
Chart of the Week: The long term headwinds facing copper shares
The key factors challenging the bull case for copper demand.
stocks
Australia’s oldest REIT undervalued
This REIT remains undervalued as trophy properties shine through.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,930.90 | 9.20 | 0.10% |
| CAC 40 | 8,419.74 | 82.45 | 0.99% |
| DAX 40 | 25,340.11 | 299.83 | 1.20% |
| Dow JONES (US) | 52,305.24 | 13.96 | -0.03% |
| FTSE 100 | 10,544.42 | 66.08 | 0.63% |
| HKSE | 23,055.03 | 174.01 | 0.76% |
| NASDAQ | 26,040.03 | 173.69 | -0.66% |
| Nikkei 225 | 68,733.15 | 1,741.81 | -2.47% |
| NZX 50 Index | 13,582.19 | 28.31 | -0.21% |
| S&P 500 | 7,483.23 | 16.13 | -0.22% |
| S&P/ASX 200 | 8,724.50 | 13.90 | 0.16% |
| SSE Composite Index | 4,028.90 | 83.54 | -2.03% |